source
- ARPA-H launches $160 million THRIVE program to fund seven labs developing custom gene-editing therapies for rare diseasesARPA-H, the U.S. Advanced Research Projects Agency for Health, announced a new initiative called THRIVE with up to $160 million in funding. The program will support seven research teams over five…
- Ipsen's Dysport shows positive Phase 3 results in migraine, Tarsus acquires iRenix for $75MIpsen reported that its injectable neurotoxin Dysport met the primary endpoint in a Phase 3 trial aimed at reducing monthly migraine days. The trial demonstrated a statistically significant reduct…